Seltorexant

Source: Wikipedia, the free encyclopedia.
Seltorexant
Clinical data
Other namesMIN-202; JNJ-42847922; JNJ-922
Routes of
administration
By mouth[1]
Drug classOrexin antagonist
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
MetabolismCYP3A4[2]
Elimination half-life2–3 hours[2]
Identifiers
  • [5-(4,6-Dimethylpyrimidin-2-yl)-hexahydropyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-ylphenyl)methanone
JSmol)
  • c4c(C)nc(nc4C)N5CC2CN(CC2C5)C(=O)c1c(cccc1F)-n3nccn3
  • InChI=1S/C21H22FN7O/c1-13-8-14(2)26-21(25-13)28-11-15-9-27(10-16(15)12-28)20(30)19-17(22)4-3-5-18(19)29-23-6-7-24-29/h3-8,15-16H,9-12H2,1-2H3/t15-,16+
  • Key:SQOCEMCKYDVLMM-IYBDPMFKSA-N

Seltorexant, also known by its developmental code names MIN-202 and JNJ-42847922, is an

orexin antagonist medication which is under development for the treatment of depression and insomnia.[3][2] It is a selective antagonist of the orexin OX2 receptor (2-SORA).[2][4][1] The medication is taken by mouth.[1] As of February 2022, seltorexant is in phase 3 clinical trials for treatment of major depressive disorder (MDD) and phase 2 trials for treatment of insomnia.[3] It was also under investigation for the treatment of sleep apnea, but no recent development has been reported for this indication.[3] Seltorexant is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceuticals.[3]

Seltorexant is being explored at doses of 5 to 80 mg.

Seltorexant shows over 100-fold greater

small-molecule compound and is structurally related to other clinically used orexin receptor antagonists.[5][2]

See also

References

External links